Skip to content

Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology

Epidemiology and Genomic Surveillance of Methicillin-sensitive Staphylococcus Aureus in ICU Neonatology : Rectal and Nasal Screening, Cross Transmission and Decolonisation

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06267352
Acronym
NEOSAUR
Enrollment
120
Registered
2024-02-20
Start date
2024-03-31
Completion date
2026-06-30
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU

Keywords

cross-transmission, prevention and infection control, bacterial typing

Brief summary

Newborns hospitalized in Neonatology are particularly vulnerable to infections, in particular healthcare associated infection (HAI). Staphylococcus aureus represents the 2nd microorganism responsible for sepsis, this infection is particularly serious and like any HAI, it increases the length of hospitalization of newborns and neonatal morbidity. In September 2020, the CDC published recommendations for the prevention and control of Staphylococcus aureus infections in neonatal intensive care unit/ICU. They specify the indications for implementing a MSSA surveillance strategy as well as the screening and management methods. Despite the absence of a defined strategy at the national level, our establishment chose to initiate management measures several years ago following serious infections and MSSA epidemics in neonatal intensive care unit/ICU. With the aim of improving the efficiency of care and evaluating the strategy chosen at the establishment, it is necessary to describing * the epidemiology of MSSA carriage and infections * cross-transmission of MSSA strains between patients * the success rate of decolonization * the sensitivity of detection of digestive carriage by stool swabbing in order to limit the number of samples from newborns.

Interventions

None listed

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* newborns hospitalized in neonatal ICU * MSSA carrier

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
frequency of MSSA cross transmission as assessed by WGSMonth 24Number of patients with acquired MSSA / total number of MSSA carriers

Contacts

Primary ContactCamille JEANNE-LEROYER
jeanneleroyer-c@chu-caen.fr0231065947

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026